This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): TVP-1901, Valrocemide
Description: Valrocemide is a potent, broad-spectrum, anti-convulsant agent. It is active in a wide range of relevant epilepsy models in animals, all considered to be predictive of clinical efficacy, and may have a novel mechanism of action. Based on these models it has been selected by the epilepsy branch of the NIH as a candidate drug with a high anti-epileptic potential.
Preliminary pre-clinical studies indicated a potential activitiy of valrocemide in the treatment of neuropathic pain. Research is ongoing to explore its potential activity in other indications, including bipolar disease.
Deal Structure: Valrocemide's rights are owned by the Yissum Research and Development Company of the Hebrew University of Jerusalem.
In August 2003, Teva, which had acquired rights to the drug from Yissum, and Acorda Therapeutics entered into a strategic collaboration to co-develop and co-promote valrocemide for several indications. The parties plan to initially develop the product for the treatment of epilepsy.In addition, Acorda has granted Teva a right of first negotiation for the co-development and co-promotion of its lead product candidate, Fampridine-SR in North America. Financial terms were not disclosed.
Teva decided to forego the drug in June 2005, after partial Phase II clinical trials, and before Phase III trials began, and this partnership was dissolved in September 2005.
On July 11, 2006, Shire entered into an exclusive, worldwide, royalty-bearing license with Yissum for valrocemide and other related compounds. Under the agreement, Yissum will receive an initial payment of...See full deal structure in Biomedtracker
Pink Sheet Weekly Trademark Review Nov. 26, 2013
Additional information available to subscribers only: